Carey Thomas D. 4
4 · STANDARD BIOTOOLS INC. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Standard BioTools (LAB) Director Thomas D. Carey Receives RSU Award
What Happened
Thomas D. Carey, a director of Standard BioTools, was granted 51,282 restricted stock units (RSUs) on 2026-02-26 at an implicit price of $1.17 per share, with a total value of $60,000. This was an award (transaction code A) issued in lieu of cash compensation for board services, not an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-26; reported on Form 4 filed 2026-03-02 (filed within the SEC’s two-business-day window).
- Security: 51,282 RSUs; grant value = $60,000; per-share implied value reported = $1.17.
- Shares owned after transaction: not specified in the provided filing.
- Footnotes:
- F1: RSUs vest 25% on the last day of the last month of each fiscal quarter of 2026, subject to continued service.
- F2: RSUs were issued because Carey elected to receive RSUs instead of $60,000 cash board compensation.
- Transaction type: Award/acquisition (A) — compensation, not a market trade.
Context
RSU grants are compensation and typically reflect pay arrangements rather than a direct sentiment signal; the units vest over four quarterly installments in 2026 if Carey remains in service. Because these shares were issued in lieu of cash, they don’t indicate a purchase financed by the director’s conviction in the stock; they simply convert cash pay into equity.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-02-26$1.17/sh+51,282$60,000→ 245,340 total
Footnotes (2)
- [F1]Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2026, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $60,000 in cash compensation for certain services as a board member.